RECORDATI Sustainability Profile
Recordati S.p.A., a prominent player in the pharmaceutical industry, is headquartered in Luxembourg (LU) and operates extensively across Europe, North America, and other global markets. Founded in 1926, Recordati has established itself as a leader in the development and marketing of innovative medicines, particularly in the fields of rare diseases and specialty pharmaceuticals. The company’s core offerings include a diverse range of prescription drugs, with a strong emphasis on treatments for rare diseases, urology, and cardiovascular conditions. Recordati's commitment to research and development sets it apart, enabling the introduction of unique therapies that address unmet medical needs. With a robust market position, Recordati has achieved significant milestones, including strategic acquisitions and partnerships that enhance its portfolio and global reach.
DitchCarbon Score
How does RECORDATI's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
RECORDATI's score of 58 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
RECORDATI's reported carbon emissions
In 2024, RECORDATI reported total carbon emissions of approximately 346,511,000 kg CO2e, with Scope 1 emissions at about 37,280,000 kg CO2e, Scope 2 emissions (market-based) at approximately 1,714,000 kg CO2e, and significant Scope 3 emissions totalling around 307,517,000 kg CO2e. The company has set ambitious targets to reduce its Scope 1 and Scope 2 emissions by 42% by 2030, using 2023 as the baseline year. This commitment aligns with the Science Based Targets initiative (SBTi) and reflects a strong commitment to climate action. In the previous year, 2023, RECORDATI's emissions were approximately 38,396,000 kg CO2e for Scope 1 and about 1,789,000 kg CO2e for Scope 2 (market-based). Notably, the company achieved a reduction of about 3.1% in Scope 1 emissions and approximately 1.9% in Scope 2 emissions from 2022 to 2023. RECORDATI's climate strategy includes a commitment to purchase 100% renewable electricity for its production and packaging sites by 2025, further enhancing its sustainability efforts. The emissions data is cascaded from its parent company, Recordati Industria Chimica e Farmaceutica S.p.A., ensuring a comprehensive approach to emissions reporting and reduction initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 27,785,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,302,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 |
How Carbon Intensive is RECORDATI's Industry?
How Carbon Intensive is RECORDATI's Location?
RECORDATI's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.
Top Scope 3 Categories
RECORDATI's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
RECORDATI has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Horizon Therapeutics Public Limited Company
Frequently Asked Questions
Common questions about RECORDATI's sustainability data and climate commitments